RCC · Oncology · 3 drugs · 4 indications
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|---|---|---|---|---|
| Raludotatug deruxtecan | DSNKY, AZN | CDH6-directed (DXd payload) | ADC | IV | PHASE2 |
| Keytruda | MRK | PD-1 inhibitor | Antibody | IV | APPROVED |
| Welireg | MRK | HIF-2α inhibitor | Small molecule | PO | APPROVED |